Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
In this double-blind study (N=575), posaconazole was non-inferior to voriconazole in terms of all-cause mortality up until day 42 (15% v 21% respectively; treatment difference −5.3% [95% CI −11.6 to 1.0]; p<0.0001), with a lower incidence of treatment-related adverse events.
Source:
The Lancet